Показано 0 из 0
Дата |
---|
16:30 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
19.04.2024 |
18.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
8.02
|
8.68
|
8.02
|
8.02
|
8.02
|
8.02
|
|
|
|
|
8.02
|
8.70
|
8.12
|
8.12
|
8.12
|
8.12
|
|
|
|
|
8.18
|
8.68
|
8.12
|
8.12
|
8.12
|
8.12
|
|
|
|
|
8.02
|
8.70
|
8.04
|
8.04
|
8.04
|
8.04
|
|
|
|
|
8.06
|
8.70
|
8.04
|
8.04
|
8.04
|
8.04
|
|
|
|
|
8.06
|
8.70
|
8.22
|
8.22
|
8.22
|
8.22
|
|
|
|
|
8.34
|
8.70
|
8.28
|
8.28
|
8.28
|
8.28
|
|
|
662.40
|
2.00
|
8.24
|
8.72
|
8.22
|
8.22
|
8.22
|
8.22
|
|
|
|
|
8.22
|
8.76
|
8.12
|
8.12
|
8.12
|
8.12
|
|
|
|
|
8.12
|
8.76
|
8.28
|
8.28
|
8.90
|
8.90
|
|
|
445.00
|
2.00
|
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company’s drugs are intended to provide patients with various treatment options. Its pipeline is protected by a portfolio of patents and comprises three principal drug candidates that are in various stages of development.